# BioLargo

BioLargo is an Asset Manager based in Westminster, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Westminster, United States
- **Region:** North America
- **Address:** Westminster, CA, United States
- **Founded:** 2007
- **Assets under management:** Undisclosed
- **Website:** biolargo.com
- **LinkedIn:** https://www.linkedin.com/company/biolargo-inc

## Regulatory record

- **Reports private funds:** No

## About

BioLargo was founded in 2007 by Dennis Calvert, who has served as President and CEO since incorporation. The company is headquartered in Westminster, California, and trades on the OTCQB market. Its founding thesis — acquiring, developing, and commercializing technologies that solve environmental problems with minimal chemical or energy inputs — has produced a portfolio centered on advanced water and air treatment systems. The company deploys capital through wholly owned subsidiaries that each target a distinct vertical. BioLargo Water focuses on industrial and municipal water treatment, where the Aqueous Electrostatic Concentrator competes against legacy carbon filtration and reverse osmosis by achieving higher PFAS removal rates at lower energy cost. BioLargo Engineering provides environmental consulting and remediation services for industrial sites. Clyra Medical Technologies, a majority-owned subsidiary, applies the company's iodine-based antimicrobial chemistry to healthcare products including wound-care and surgical disinfectants. ONM Environmental addresses odor and volatile-organic-compound control for landfills, wastewater plants, and agricultural operations. The company generates revenue through product sales, service contracts, and technology licensing agreements rather than fund structures. BioLargo reported total assets of roughly $8 million in its most recent filings, with cash holdings under $2 million, making it a nano-cap enterprise. The company has historically funded operations through equity issuances and government grants rather than institutional LP commitments. In May 2024, the company announced its first multi-year municipal water-treatment purchase order, with a Minnesota city adopting the AEC system for PFAS remediation, marking a shift from pilot-stage projects to recurring commercial revenue. The company's structural posture is unusual — it is a publicly traded micro-cap that functions internally like a venture studio, spinning out subsidiaries into distinct operating companies while retaining majority control. This architecture allows each subsidiary president to pursue independent commercial partnerships, but centralizes intellectual property and engineering at the parent level, creating a licensing flywheel that keeps administrative costs consolidated. Calvert's decision to keep the parent company public rather than private provides permanent access to retail capital markets, a funding path most environmental-technology startups forgo.

## Sectors

- Clean Tech
- Water Technology

## People

- Dennis P. Calvert — President and CEO

## Questions

### What does BioLargo actually sell?

BioLargo sells water-treatment equipment, engineering services, and antimicrobial products through its subsidiaries. The Aqueous Electrostatic Concentrator removes contaminants like PFAS from industrial and municipal water. The engineering subsidiary provides site remediation. The medical subsidiary sells sterilizing wound-care and surgical products. Revenue comes from equipment sales, service contracts, and licensing.

### How is BioLargo structured, and who runs the subsidiaries?

BioLargo is the publicly traded parent company. Dennis Calvert runs it as CEO. Each subsidiary operates with its own president who manages day-to-day execution — the model resembles a venture studio where the parent provides centralized engineering, intellectual property, and capital, while subsidiary leaders focus on commercial go-to-market.

### How does BioLargo fund its operations?

BioLargo funds operations primarily through equity issuances — it is a publicly traded micro-cap that raises capital on the OTCQB market — and through government research grants and contracts. As of its most recent disclosures, it holds under $2 million in cash and has historically relied on periodic capital raises rather than debt or institutional investment.

## Related profiles

- [Metalpha Technology Holding](https://altss.com/profile/metalpha-technology-holding-ltd)
- [AVAI BIO](https://altss.com/profile/avai-bio-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/biolargo-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology